Results 1 to 10 of about 6,944 (246)

A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD [PDF]

Kidney International Reports
Introduction: Finerenone demonstrated kidney and cardiovascular benefits in participants with chronic kidney disease (CKD) and type 2 diabetes (T2D) on optimized renin-angiotensin system (RAS) inhibition in FIDELITY, a pooled individual-level analysis of
Ajay K. Singh, Stefan D. Anker, Bertram Pitt, Peter Rossing, Luis M. Ruilope, Christiane Ahlers, Youssef M.K. Farag, Marc Lambelet, Meike D. Brinker, Katja Rohwedder, Gerasimos Filippatos   +10 more
doaj   +3 more sources

GLP-1RA and the possible skin aging [PDF]

Endocrine
Abstract “Ozempic face” and facial aging have been observed as side effects in many patients after glucagon like peptide 1 receptor agonists (GLP-1RA) therapy for type 2 diabetes mellitus (T2DM) and obesity. However, those medications can reduce systemic inflammation and possibly promote skin health.
Paschou, Ioanna A., Sali, Evangelia, Paschou, Stavroula A., Tsamis, Konstantinos I., Peppa, Melpomeni, Psaltopoulou, Theodora, Nicolaidou, Electra, Stratigos, Alexander J.   +7 more
openaire   +3 more sources

Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study.

PLoS ONE, 2020
BACKGROUND:We investigated changes in clinical characteristics of SGLT2i and GLP-1RA real-world initiators in Denmark before/after landmark cardiovascular outcome trials.
Jakob S Knudsen, Lisbeth M Baggesen, Maria Lajer, Larisa Nurkanovic, Anastasia Ustyugova, Henrik T Sørensen, Reimar W Thomsen   +6 more
doaj   +3 more sources

GLP-1RA Use and Thyroid Cancer Risk

JAMA Otolaryngology–Head & Neck Surgery
ImportanceThe increasing use of glucagon-like peptide-1 receptor agonists (GLP-1RA) demands a better understanding of their association with thyroid cancer.ObjectiveTo estimate the risk of incident thyroid cancer among adults with type 2 diabetes being treated with GLP-1RA vs other common glucose-lowering medications.Design, Setting, and ...
Juan P, Brito, Jeph, Herrin, Kavya Sindhu, Swarna, Naykky M, Singh Ospina, Victor M, Montori, David, Toro-Tobon, Guillermo E, Umpierrez, Rodolfo J, Galindo, Yihong, Deng, Mindy M, Mickelson, Hui, Shao, Eric C, Polley, Rozalina G, McCoy   +12 more
openaire   +3 more sources

Promising results but caution needed in GLP-1RA large scale epidemiology

Trends in Endocrinology & Metabolism
Investigating the association between glucagon-like peptide 1 receptor agonists (GLP1-RAs) and incident disease across 175 health outcomes in US Veterans with diabetes, Xie et al. recently reported lower risk for cardiokidney disease and substance use disorders, but higher risk for pancreatitis, gastrointestinal disorders, and arthritis.
Naveed Sattar, Salil V. Deo
openalex   +3 more sources

The effects of GLP‐1RA on inflammatory skin diseases: A comprehensive review [PDF]

Journal of the European Academy of Dermatology and Venereology
Abstract Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) are commonly used as treatment for type 2 diabetes mellitus and obesity. GLP‐1RA have been found to be valuable therapeutic approaches not only for glucose control, but also for weight loss and cardiovascular risk reduction.
Ioanna A. Paschou, Evangelia Sali, Stavroula A. Paschou, Theodora Psaltopoulou, Electra Nicolaidou, Alexander J. Stratigos   +5 more
openaire   +4 more sources

GLP-1RA Medications Significantly Reduce Fracture Risk in the Diabetic Foot and Ankle Patient Population [PDF]

Foot & Ankle Orthopaedics
Research Type: Level 3 - Retrospective cohort study, Case-control study, Meta-analysis of Level 3 studies Introduction/Purpose: Diabetes mellitus (DM) is associated with an elevated risk for sustaining a fracture, driven by both direct and indirect ...
Samantha Olson BS, Alexandra Vaughan-Masamitsu BS, Michael Levidy MD, Lincoln Dutcher MD, Jana Davis MD   +4 more
doaj   +2 more sources

Addressing Confounders in GLP‐1RA Effects on ALD Outcomes [PDF]

Liver International
Chi‐Kuei Hsu, Chia‐Chih Kuo, Chih‐Cheng Lai   +2 more
openalex   +3 more sources

GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS

Frontiers in Pharmacology, 2022
Background: GLP-1 receptor agonists (GLP-1RA) have demonstrated cardiovascular benefits, but the relationship between GLP-1RA and tumors is controversial.
Zheng Yang, Yuhuan Lv, Meng Yu, Mei Mei, Linyu Xiang, Subei Zhao, Rong Li   +6 more
doaj   +1 more source

Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United StatesPlain-Language Summary

Kidney Medicine, 2023
Rationale & Objective: Information regarding disparities in initiating sodium/glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) in patients with chronic kidney disease (CKD) is limited.
Julie Z. Zhao, Eric D. Weinhandl, Angeline M. Carlson, Wendy L. St. Peter   +3 more
doaj   +1 more source